BOTHELL, Wash. and IRVINE, Calif., May 19,
2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:
BLFS), a leading developer, manufacturer and marketer of
proprietary clinical grade cell and tissue hypothermic storage and
cryopreservation freeze media and a related cloud hosted
biologistics cold chain management app for smart shippers
("BioLife" or the "Company"), today announced that through its
biologistex joint venture, it will partner with MNX Global
Logistics to support the registrational phase 3 clinical trial
being conducted by ImmunoCellular Therapeutics (NYSE MKT:
IMUC) for their ICT-107 dendritic cell-based immunotherapy for
newly diagnosed glioblastoma.
MNX will use the biologistex evo Smart Shipper and biologistex
cold chain SaaS to offer an enhanced managed logistics service for
shipping the apheresis starting material, from which the ICT-107
dendritic cell-based therapy is manufactured to produce a
personalized treatment for each patient in the clinical trial.
Marta Schilling, Vice President,
Cell Therapy Manufacturing at ImmunoCellular Therapeutics,
commented on their selection of this integrated solution by
stating, "We have been well served by MNX for years. Through
their partnership with BioLife, we were introduced to the evo Smart
Shipper and biologistex cold chain SaaS. This is a
state-of-the-art approach that we will use to enhance MNX's
logistics services to ensure that our time and
temperature-sensitive apheresis starting material arrives intact
and according to specifications at our clinical manufacturing
partner sites."
Mike Rice, BioLife President
& CEO, commented, "We are very pleased to partner with MNX to
enable a higher level of quality assurance in the cold chain
logistics practices of ImmunoCellular for their registrational
phase III trial. We commend ImmunoCellular for being an early
adopter of evo and biologistex and believe we can drive adoption to
become a best practice in the regenerative medicine
industry."
Larry Glasscock, MNX Senior Vice
President, remarked, "This is an early example of how MNX can
leverage our existing relationships to increase awareness for evo
and biologistex. BioLife recently reciprocated and introduced
MNX to a BioLife cell therapy customer, and we see a great
opportunity to cross-promote our complementary product and service
offerings in our target markets."
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that
is developing immune-based therapies for the treatment of brain and
other cancers. The phase 3 registrational trial of lead product
candidate, ICT-107, a patient-specific, dendritic cell-based
immunotherapy targeting multiple tumor-associated antigens on
glioblastoma stem cells, is open for patient screening.
ImmunoCellular's pipeline also includes: ICT-121, a
patient-specific, dendritic cell-based immunotherapy targeting the
CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a
patient-specific, dendritic cell-based immunotherapy targeting
antigens on ovarian cancer stem cells; and the Stem-to-T-cell
research program which engineers the patient's hematopoietic stem
cells to generate antigen-specific cancer-killing T cells. To learn
more about ImmunoCellular, please visit www.imuc.com.
About MNX Global Logistics
MNX is a premier global provider of specialized, expedited
transportation and logistics services. Clients include
multinational leaders in the aviation, life science, medical
device, secure custody and control, technology, luxury fashion and
entertainment industries. These organizations rely on MNX's
exceptional record of transporting critical items around the
world. www.mnx.com
About BioLife Solutions
BioLife Solutions develops, manufactures and markets
biopreservation media products and smart shipping containers
connected to a cloud hosted cold chain management app to improve
the quality of delivery logistics for cells, tissues, and organs.
The Company's proprietary HypoThermosol® and
CryoStor® platform of solutions are highly valued in the
biobanking, drug discovery, and regenerative medicine markets.
BioLife's biopreservation media products are serum-free and
protein-free, fully defined, and are formulated to reduce
preservation-induced cell damage and death. BioLife's
enabling technology provides commercial companies and clinical
researchers significant improvement in shelf life and
post-preservation viability and function of cells, tissues, and
organs.
Our biologistex cloud based cold chain management service is an
integrated logistics and tracking and trace web app used by
shippers of time and temperature sensitive biologic
materials. The evo Smart Shipper is a state of the art
precision thermal shipping container with embedded payload
monitoring, GPS location tracking, and cellular communication
electronics that transmit critical shipment information to the
cloud. This SaaS app enables users to monitor high value
shipments during transit and configure actionable alerts for
downstream recipients for location, approaching destination,
delivery, package open, and remaining shelf life or stability via
the patent pending StableAlert™ countdown timer. For more
information please visit www.biolifesolutions.com, and follow
BioLife on Twitter.
This press release contains forward-looking statements,
including, but not limited to, statements concerning new products,
the company's anticipated business and operations, the potential
utility of and market for its products and services, potential
revenue growth and market expansion, market adoption of
biologistex, commercial manufacturing of our customers' products,
potential proceeds from the credit facility, and projected
financial results, cash flow and liquidity, including the potential
for reaching positive cash flow from operations next year. All
statements other than statements of historical fact are statements
that could be deemed forward-looking statements. These statements
are based on management's current expectations and beliefs and are
subject to a number of risks, uncertainties and assumptions that
could cause actual results to differ materially from those
described in the forward-looking statements, including among other
things, uncertainty regarding market adoption of products;
uncertainty regarding third party market projections; market
volatility; competition; litigation; and those other factors
described in our risk factors set forth in our filings with the
Securities and Exchange Commission from time to time, including our
Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We
undertake no obligation to update the forward-looking statements
contained herein or to reflect events or circumstances occurring
after the date hereof, other than as may be required by applicable
law.
Media &
Investor Relations
|
|
|
Roderick de
Greef
|
|
|
Chief Financial
Officer
|
|
|
(425)
686-6003
|
|
|
rdegreef@biolifesolutions.com
|
|
|
|
|
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biolife-solutions-and-mnx-global-logistics-partner-to-support-immunocellular-therapeutics-with-cold-chain-logistics-in-ict-107-phase-3-clinical-trial-in-glioblastoma-300271359.html
SOURCE BioLife Solutions, Inc.